

BIOCONVERSION AND BIOSYNTHESIS
OF 16-MEMBERED MACROLIDE
ANTIBIOTIC, TYLOSIN, USING
ENZYME INHIBITOR: CERULENIN

Sir:

The antibiotic cerulenin¹ is a specific inhibitor of what is called "condensing enzyme" which is involved in the condensing step between acyl-ACP and malonyl-ACP in the biosynthesis of fatty acids. It also inhibits the biosynthesis of substances such as leucomycin², 6-methylsalicylic acid³, candicidin⁴ and flavone⁵, which are presumably derived *via* "polyketide". It was thus expected that cerulenin might offer us an effective device to explore the biosynthesis of macrolide antibiotics as an alternative to blocked mutants which have been conventionally utilized to study the biosynthesis of macrolides^{6,7} and tetracycline⁸.

Taking advantage of such salient inhibitory property of cerulenin, we have studied the final steps of the biosynthetic pathway of tylosin (**1**) and relomycin (**2**), the dihydro derivative of **1**, which is accumulated toward the end of fermentative production of **1**⁹. It has been established that the aldehyde group of 16-membered macrolide¹⁰ originates from the methyl group of butyrate. However, the question as to whether the hydroxyl group of **2** is generated during the oxidation process from the methyl group into the aldehyde group or it is formed through the reduction of the aldehyde precursor after oxidation has remained unknown. So, we examined how the mutual conversion of **1** and **2**

is accomplished in the biosynthetic processes.

The producing strain *Streptomyces fradiae* C-373, which provides both **1** and **2**, was cultured at 27°C using a 500-ml Sakaguchi flask containing 100 ml of culture medium composed of lactose 2.0%, Pharmamedia 4.0%, MgSO₄·7H₂O 0.5%, KCl 0.5%, NaCl 0.5%, CaCO₃ 0.75% and tap water (pH 7.5). At the beginning of fermentation, 20 mcg/ml of cerulenin was added to the culture broth to prevent the formation of antibiotics and after that the same amount of cerulenin was added every 24 hours. After incubation for 48 hours or 168 hours, 100 mcg/ml of **1** and its related compounds obtained by acid hydrolysis of **1** or **2** (See Fig. 1), were added to the culture, and then the incubation was continued for additional 24 hours. The product in the culture broth was extracted with benzene and the concentrated extract was subjected to thin-layer chromatography (Silica gel G, the bottom layer of a mixture of chloroform - methanol - 3% aq. ammonia = 2:1:1 as a developer). The components on the chromatogram were then quantitatively analysed on a Shimadzu double-beam chromatogram scanner (model CS-910) at 282 nm where the maximum UV absorption of **1** and its related compounds occurs. The transformed **1** and **2** were estimated from the ratio of the peak area to the total peak area of the potential metabolites. Similarly, the relative ratio of **1** to **2** or **2** to **1** was also estimated and shown in parenthesis (%) in Table 1.

When mycaminosyl tylonolide **4** was added to 48-hour culture, 23.6% of **4** was converted to **1**. However, the conversion of **4** to **2** was only 2.6%

Fig. 1. Structures of tylosin and its related compounds




Table 1. The conversion of tylosin and its related compounds into tylosin and relomycin by *S. fradiae* under the inhibited conditions of lactone synthesis by cerulenin.

Compound added	Tylosin 1		Relomycin 2	
	48 hours	168 hours	48 hours	168 hours
Mycaminosyl tylonolide, 4	23.6 ^{a)} (90.2) ^{b)}	14.8 (41.6)	2.6 (9.8)	20.8 (58.4)
Demycarosyl tylosin, 3	21.3 (74.9)	15.2 (39.3)	7.2 (25.1)	23.5 (60.7)
Mycaminosyl relonolide, 6	9.3 (22.8)	4.6 (11.3)	31.4 (77.2)	35.7 (88.7)
Demycarosyl relomycin, 5	11.0 (27.4)	3.5 (8.2)	29.2 (72.6)	39.3 (91.8)
Tylosin, 1	80.0 (89.3)	65.6 (86.3)	9.6 (10.7)	10.4 (13.7)
Relomycin, 2	0 (0)	0 (0)	81.8 (100)	66.7 (100)
None ^{c)}	0 (0)	0 (0)	0 (0)	0 (0)
Control ^{d)}	59.7 (82.8)	8.9 (34.3)	12.4 (17.2)	17.0 (65.7)

^{a)} Conversion ratio (%) of each compounds was calculated from total peak area detected with Shimadzu double-beam chromatoscanner (model CS-910) at 282 nm.

^{b)} Relative ratio of **1** or **2** to **2** or **1** (%).

^{c)} No compounds added.

^{d)} No cerulenin and compounds added.

in the same culture broth. The relative ratio of **1** to **2** was 90.2%: that of **2** to **1** was 9.8%, suggesting that the cells in the early stage has a rapid activity of glycoside bond formation. On the other hand, in the 168-hour culture the relative ratio of **1** and **2** changed drastically: **1** to **2** 41.6%, **2** to **1** 58.4%. This indicates that the reduction of aldehyde group into hydroxyl group takes place in this later stage besides the glycosidation. Similarly, when demycarosyl tylosin **3** was added to the 48-hour culture, its conversion to **1** was better than that to **2**, and also in the 168-hour culture **2** was again predominantly produced. The similar trends were observed when mycaminosyl relonolide **6** or demycarosyl relomycin **5** was added to the 48-hour or 168-hour culture; the conversion to **2** seems much more predominant than that to **1** because of rapid glycosidation. However, it is obvious from the table that the relative amount of **1** was decreased in the 168-hour culture, and the percentage of **2**, on the contrary, was increased under the same conditions. In contrast, addition of **1** or **2** to the 48-hour or 168-hour culture demonstrated minor mutual conversion or complete absence of mutual conversion between these compounds.

These results disclose that; (1) the conversion of alcohol to aldehyde is predominant in the early stage of incubation, (2) in the later stage, however, reduction of aldehyde to alcohol is predominant. In the recent paper by SENO *et al.*¹¹⁾ it is reported that **2** is derived directly

from **1**, however, the present results indicate that the redox-reaction of alcohol and aldehyde, is most likely to precede the binding of mycarose.

Results from the present investigation also point out that cerulenin can be successfully applied to biosynthetic studies of compounds produced *via* polyketide in place of previously employed methods involving blocked mutants or radio isotopes.

Acknowledgments

We wish to thank Dr. C. W. PETTINGA of Eli Lilly and Company for a generous gift of tylosin-producing strain and a sample of tylosin.

SATOSHI ŌMURA*
 CHIAKI KITAO
 JUN MIYAZAWA
 HARUMITSU IMAI
 HIDEO TAKESHIMA

Kitasato University and
 The Kitasato Institute
 Minato-ku, Tokyo 108, Japan

(Received November 28, 1977)

References

- 1) ŌMURA, S.: The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. *Bact. Rev.* 40: 681~697, 1976

- 2) ŌMURA, S. & H. TAKESHIMA: Inhibition of the biosynthesis of leucomycin, a macrolide antibiotic, by cerulenin. *J. Biochem.* 75: 193~195, 1974
- 3) OHNO, H.; T. OHNO, J. AWAYA & S. ŌMURA: Inhibition of 6-methylsalicylic acid synthesis by the antibiotic cerulenin. *J. Biochem.* 78: 1149~1152, 1975.
- 4) MARTIN, J.R. & E. MCDANIEL: Specific inhibition of candicidin biosynthesis by the lipogenic inhibitor cerulenin. *Biochim. Biophys. Acta* 411: 186~194, 1975
- 5) KREUZALER, F. & K. HAHLBROCH: Enzymic synthesis on aromatic ring from acetate units. Partial purification and some properties of flavanone synthase from cell suspension culture of *Petroselinum hortense*. *Eur. J. Biochem.* 56: 205~213, 1975
- 6) MARTIN, J.R.; T. J. PERUN & R. S. EGAN: (8S)-8-Hydroxy-5,6-dideoxy-5-oxoerythronolide B, a shunt metabolite of erythromycin biosynthesis. *Tetrahedron* 28: 2937~2948, 1972
- 7) FURUMAI, T.; K. KANEDA & M. SUZUKI: Studies on the biosynthesis of basic 16-membered macrolide antibiotics, platenomycins. IV. Biosynthesis of platenomycins. *J. Antibiotics* 28: 789~797, 1975
- 8) McCORMIK, J. R. D.; Antibiotic (D. GOTTLIEB & P. SBAW eds.) Vol. II, p. 113, Springer-Verlag, New York, 1967
- 9) JENSEN, A. L.; M. A. DARKEN, J. S. SCHULTZ & A. J. SHAY: Relomycin: Flask and tank fermentation studies. *Antimicrob. Agents & Chemother.* -1963: 49~53, 1964
- 10) a) ŌMURA, S.; A. NAKAGAWA, H. TAKESHIMA, K. ATSUMI, J. MIYAZAWA, F. PIRIOU & G. LUKACS: Biosynthetic studies using ^{13}C enriched precursors on the 16-membered macrolide antibiotic leucomycin A_3 . *J. Am. Chem. Soc.* 97: 6600~6602, 1975
b) ŌMURA, S.; A. NAKAGAWA, H. TAKESHIMA, J. MIYAZAWA, C. KITAO, F. PIRIOU & G. LUKACS: A ^{13}C nuclear magnetic resonance study of the biosynthesis of the 16-membered macrolide antibiotic tylosin. *Tetrahedron Lett.* 1975: 4503~4506, 1975
- 11) SENO, E. T.; R. L. PIEPER & F. M. HUBER: Terminal stages in the biosynthesis of tylosin. *Antimicrob. Agents & Chemother.* 11: 455~461, 1977